See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
MLS
Baseball
Donald Trump
Hockey
Tennis
Israel-Hamas Conflict
Hamas
Ukraine War
Published • loading... • Updated

Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment

Summary by targetedonc.com
Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment

Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

News
For You
Search
BlindspotLocal